Atara Falls As PINTA Sinks In Phase II
This article was originally published in Scrip
Atara Biotherapeutics Inc. fell 36.8% to $21 per share on Dec. 14 after the company suspended work on PINTA 745 for the reversal of peptide-energy wasting (PEW), leaving only two of the company's Christopher Columbus-themed drug candidates – previously in development by subsidiaries known as Nina and Santa Maria – afloat along with newer oncology and immunotherapy programs.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.